CAMP (STOCKS)
CAMP4 Therapeutics Corporation Common Stock
$3.960000
-0.230000 (-5.49%)
Prev close: $4.190000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Josh Mandel-Brehm
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $205.63M
- Employees
- 55
- P/E (TTM)
- -1.74
- P/B (TTM)
- 7.04
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
5
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.32 | $-0.21 | -0.1058 | -49.39% |
|
Dec 2025 (Q4)
|
$-0.86 | $-0.31 | -0.5506 | -177.96% |
|
Sep 2025 (Q3)
|
$-0.55 | $-0.49 | -0.0621 | -12.73% |
|
Jun 2025 (Q2)
|
$-0.62 | $-0.69 | +0.0654 | +9.54% |
Financial Statements
| Revenues | $264.74M |
| Benefits Costs and Expenses | $365.05M |
| Cost Of Revenue | $170.02M |
| Costs And Expenses | $365.05M |
| Gross Profit | $94.72M |
| Nonoperating Income/Loss | -$5.14M |
| Operating Expenses | $189.89M |
| Research and Development | $20.03M |
| Other Operating Expenses | $148.11M |
| Operating Income/Loss | -$95.18M |
| Income/Loss From Continuing Operations After Tax | -$101.35M |
| Income/Loss From Continuing Operations Before Tax | -$100.32M |
| Income Tax Expense/Benefit | $1.03M |
| Income Tax Expense/Benefit, Deferred | $1.02M |
| Interest Expense, Operating | $6.28M |
| Net Income/Loss | -$101.35M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$101.35M |
| Net Income/Loss Available To Common Stockholders, Basic | -$101.35M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.71 |
| Diluted Earnings Per Share | -$2.71 |
| Basic Average Shares | 111,152,000 |
| Diluted Average Shares | 111,152,000 |
| Assets | $281.24M |
| Current Assets | $168.96M |
| Inventory | $34.06M |
| Other Current Assets | $134.90M |
| Noncurrent Assets | $112.28M |
| Fixed Assets | $25.72M |
| Non-current Prepaid Expenses | $2.29M |
| Other Non-current Assets | $84.27M |
| Liabilities | $355.38M |
| Current Liabilities | $99.70M |
| Accounts Payable | $46.70M |
| Wages | $10.11M |
| Other Current Liabilities | $42.90M |
| Noncurrent Liabilities | $255.68M |
| Long-term Debt | $230.22M |
| Other Non-current Liabilities | $25.46M |
| Equity | -$74.14M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$74.14M |
| Liabilities And Equity | $281.24M |
| Net Cash Flow From Operating Activities | $4.90M |
| Net Cash Flow From Operating Activities, Continuing | $4.90M |
| Net Cash Flow From Investing Activities | -$7.98M |
| Net Cash Flow From Investing Activities, Continuing | -$7.98M |
| Net Cash Flow From Financing Activities | -$125.00K |
| Net Cash Flow From Financing Activities, Continuing | -$125.00K |
| Net Cash Flow | -$3.21M |
| Net Cash Flow, Continuing | -$3.21M |
| Comprehensive Income/Loss | -$100.20M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$100.20M |
| Other Comprehensive Income/Loss | -$83.86M |